Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination With Bempegaldesleukin(NKTR-214) With or Without Talazoparib or Enzalutamide in Participants With Locally Advanced or Metastatic Solid Tumors

NCT04052204 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04052204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04052204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination With Bempegaldesleukin(NKTR-214) With or Without Talazoparib or Enzalutamide in Participants With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Terminated
Start date
December 30, 2019
Completion date
September 29, 2020
Enrollment
3 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer (mcrpc), squamous cell carcinoma of the head and neck (scchn)